Table 1 Characteristics of 17 patients with hepatocellular carcinoma undergoing liver transplantation
Pt No. | Pt Group | Sex | Age | Viral Hepatitis | Liver cirrhosis Child-Pugh | Pre-OLT BCLC | Histology | AFP (ng/mL) | Pre-OLT Treatment | Donor Type | Relapse Location | Post Relapse Treatment | Sorafenib Dose (mg) | Current Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Adjuvant | M | 50 | HBV | A | B | N/A | N/A | TACE | CD | Liver | TACE, R/T | 400 | PD |
2 | Adjuvant | M | 50 | HBV | A | A | Mod. Diff. | 3.29 | OP, RFA | CD | Nil | Nil | 600 | CR |
3 | Adjuvant | M | 55 | HBV | A | B | N/A | 3115 | Nil | CD | Nil | Nil | 400 | CR |
4 | Adjuvant | M | 61 | HCV | A | B | Mod. Diff. | 153 | TACE, RFA | CD | Nil | Nil | 400 | CR |
5 | Adjuvant | M | 51 | HBV | B | B | P. Diff. | 25.4 | TACE | CD | Nil | Nil | 400 | CR |
6 | Palliative | M | 56 | HBV | C | D | N/A | 12.31 | TACE | CD | Potal vein | Nil | 400 | PD |
7 | Palliative | M | 48 | HBV | A | C | N/A | 5567 | TACE, RFA | CD | Liver | TACE, R/T | 800 | Dead |
8 | Palliative | M | 51 | HBV | B | C | P. Diff. | 22.12 | TACE | LD | Lung | C/T | 400 | CR |
9 | Palliative | M | 48 | HBV | A | B | P. Diff. | 5.07 | Nil | CD | Liver | R/T, RFA | 800 | Dead |
10 | Palliative | F | 61 | HCV | B | D | N/A | 7745 | TACE, RFA | CD | Lung | Nil | 200 | Dead |
11 | Palliative | M | 55 | HBV | C | D | N/A | N/A | Nil | CD | Portal vein | R/T | 400 | Dead |
12 | Control | F | 78 | HCV | A | B | N/A | N/A | TACE | CD | Lung | Nil | Nil | Dead |
13 | Control | M | 39 | HBV | A | C | P. Diff. | 24.21 | TACE | CD | Liver | TACE, OP, C/T | Nil | Dead |
14 | Control | M | 57 | HBV | B | C | P. Diff. | 6.38 | TACE | CD | Liver | OP | Nil | Dead |
15 | Control | F | 62 | HCV | A | C | N/A | 9058 | OP, RFA | CD | Liver | TACE | Nil | Dead |
16 | Control | M | 62 | HCV | A | C | Mod. Diff. | 13.74 | TACE | CD | Nil | Nil | Nil | Dead |
17 | Control | F | 62 | HCV | C | C | P. Diff. | 98589 | Nil | LD | Lung | Nil | Nil | Dead |